2025年3月最新中科院分区数据已更新,欢迎查询使用。如果您对期刊系统有任何需求或者问题,欢迎
反馈给我们。近期推荐: | 热 SCI论文AI润色+人工QC服务 | 热 赛默飞基础学科研究有奖问卷 | 热 同行专家帮助选刊 |
![]() |
基本信息 | 登录收藏 | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字![]() | Journal for ImmunoTherapy of Cancer J IMMUNOTHER CANCER (此期刊被最新的JCR期刊SCIE收录) LetPub评分 8.4
55人评分
我要评分
声誉 9.4 影响力 8.0 速度 6.9 | |||||||||||||||||||||||||||||||||||||
期刊ISSN | 2051-1426 | 微信扫码收藏此期刊 | ||||||||||||||||||||||||||||||||||||
2023-2024最新影响因子 (数据来源于搜索引擎) | 10.3 点击查看影响因子趋势图 | |||||||||||||||||||||||||||||||||||||
实时影响因子 | 截止2025年4月18日:9.912 | |||||||||||||||||||||||||||||||||||||
2023-2024自引率 | 2.90%点击查看自引率趋势图 | |||||||||||||||||||||||||||||||||||||
五年影响因子 | 11.6 | |||||||||||||||||||||||||||||||||||||
JCI期刊引文指标 | 2.02 | |||||||||||||||||||||||||||||||||||||
h-index | 36 | |||||||||||||||||||||||||||||||||||||
CiteScore ( 2024年最新版) |
| |||||||||||||||||||||||||||||||||||||
期刊简介 |
| |||||||||||||||||||||||||||||||||||||
期刊官方网站 | https://www.springer.com/journal/40425 | |||||||||||||||||||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||||||||||||||||||
期刊投稿网址 | https://www.editorialmanager.com/JITC | |||||||||||||||||||||||||||||||||||||
期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足Journal for ImmunoTherapy of Cancer的语言要求,还能让Journal for ImmunoTherapy of Cancer编辑和审稿人得到更好的审稿体验,让稿件最大限度地被Journal for ImmunoTherapy of Cancer编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢(2篇) 。
提交文稿 | |||||||||||||||||||||||||||||||||||||
是否OA开放访问 | Yes | |||||||||||||||||||||||||||||||||||||
OA期刊相关信息![]() | 文章处理费:需要( USD2972; ) 文章处理费豁免:查看说明 其他费用:没有 期刊主题关键词:tumour immunology、cancer immunotherapy、immunotherapy biomarkers 相关链接:Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | |||||||||||||||||||||||||||||||||||||
通讯方式 | BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND, WC1H 9JR | |||||||||||||||||||||||||||||||||||||
出版商 | BioMed Central | |||||||||||||||||||||||||||||||||||||
涉及的研究方向 | Biochemistry, Genetics and Molecular Biology-Molecular Medicine | |||||||||||||||||||||||||||||||||||||
出版国家或地区 | UNITED STATES | |||||||||||||||||||||||||||||||||||||
出版语言 | English | |||||||||||||||||||||||||||||||||||||
出版周期 | ||||||||||||||||||||||||||||||||||||||
出版年份 | 2013 | |||||||||||||||||||||||||||||||||||||
年文章数 | 417点击查看年文章数趋势图 | |||||||||||||||||||||||||||||||||||||
Gold OA文章占比 | 98.98% | |||||||||||||||||||||||||||||||||||||
研究类文章占比: 文章 ÷(文章 + 综述) | 93.76% | |||||||||||||||||||||||||||||||||||||
WOS期刊SCI分区 ( 2023-2024年最新版) | WOS分区等级:1区
| |||||||||||||||||||||||||||||||||||||
中国科学院《国际期刊预警 名单(试行)》名单 | 2025年03月发布的2025版:不在预警名单中 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||||||||||||||||||
中国科学院SCI期刊分区 ( 2025年3月最新升级版) | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||||||||||||||||||
中国科学院SCI期刊分区 ( 2023年12月升级版) |
| |||||||||||||||||||||||||||||||||||||
中国科学院SCI期刊分区 ( 2022年12月旧的升级版) |
| |||||||||||||||||||||||||||||||||||||
SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2051-1426%5BISSN%5D | |||||||||||||||||||||||||||||||||||||
平均审稿速度 | 网友分享经验: 18 Weeks | |||||||||||||||||||||||||||||||||||||
平均录用比例 | 网友分享经验: | |||||||||||||||||||||||||||||||||||||
版面费/APC文章处理费信息 | 文章处理费:需要( USD2972; ) 文章处理费豁免:查看说明 其他费用:没有 LetPub提供文章处理费(APC)支持服务,可以用人民币支付版面费啦! | |||||||||||||||||||||||||||||||||||||
LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在Journal for ImmunoTherapy of Cancer顺利发表。
快看看作者怎么说吧:服务好评 论文致谢(2篇) 。 提交文稿 | |||||||||||||||||||||||||||||||||||||
期刊常用信息链接 |
|
|
|
|
中国学者近期发表的论文 | |
1. | Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation Author: Sun, Fei; Yao, Fangzhen; Zeng, Chunting; Zhao, Yang; Liang, Bishan; Li, Shaowei; Wang, Yawen; Wu, Qijing; Shi, Yulu; Yao, Zhiqi; Wang, Jiao; Jiang, Yu; Gu, Chunhui; Huang, Qiong; Liao, Wangjun; Huang, Na; Wang, Chunlin; Rong, Xiaoxiang; Wu, Jing; Tan, Yujing; Peng, Jianjun; Li, Yong; Shi, Min Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2025; Vol. 13, Issue 2, pp. -. DOI: 10.1136/jitc-2024-010126 PubMed DOI |
2. | Acetyltransferase NAT10 inhibits T-cell immunity and promotes nasopharyngeal carcinoma progression through DDX5/HMGB1 axis Author: Xie, Haijing; Zhang, Kaiwen; Yin, Haimeng; Zhang, Siyu; Pan, Si; Wu, Rui; Han, Yumo; Xu, Yi; Jiang, Weihong; You, Bo Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2025; Vol. 13, Issue 2, pp. -. DOI: 10.1136/jitc-2024-010301 PubMed DOI |
3. | Comment on Role of CD47 Gene Expression in Colorectal Cancer: A Comprehensive Molecular Profiling Study Author: Zhang, Chongjie; Li, Jianjiong Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2025; Vol. 13, Issue 1, pp. -. DOI: 10.1136/jitc-2024-011008 PubMed DOI |
4. | Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma Author: Ramaswami, Ramya; Kask, Angela Shaulov; D'Amico, Leonard; Menon, Manoj P.; Lurain, Kathryn; Yarchoan, Robert; Ekwede, Irene; Couey, Paul; Burnham, Eli; Angeldekao, Allysson; Lee, Byung Ha; Kaiser, Judith C.; Cheever, Martin; Uldrick, Thomas S.; Kwok, Li-Lian; Wright, Anna; Fling, Steven P.; Wang, Chia-Ching Jackie Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2025; Vol. 13, Issue 2, pp. -. DOI: 10.1136/jitc-2024-010291 PubMed DOI |
5. | Clofarabine induces tumor cell apoptosis, GSDME-related pyroptosis, and CD8+ T-cell antitumor activity via the non-canonical P53/STING pathway Author: Wu, Jie; Liu, Nian; Chen, Jing; Tao, Qian; Lu, Can; Li, Qiuqiu; Chen, Xiang; Peng, Cong Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2025; Vol. 13, Issue 2, pp. -. DOI: 10.1136/jitc-2024-010252 PubMed DOI |
6. | Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights Author: Wang, Xuan; Tian, Hui; Chi, Zhihong; Si, Lu; Sheng, Xinan; Hu, Han; Gu, Xiangyong; Li, Siming; Li, Caili; Lian, Bin; Zhou, Li; Mao, Lili; Tang, Bixia; Yan, Xieqiao; Wei, Xiaoting; Li, Juan; Liu, Binlei; Guo, Jun; Kong, Yan; Cui, Chuanliang Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2025; Vol. 13, Issue 2, pp. -. DOI: 10.1136/jitc-2024-010662 PubMed DOI |
7. | UBE2T/CDC42/CD276 signaling axis mediates brain metastasis of triple-negative breast cancer via lysosomal autophagy Author: Shi, Liang Liang; Chen, Yan; Xie, Ming Xing; Chen, Qian Zhi; Qiao, Xin Wei; Cheng, Qi Hong; Li, Lin; Fu, Rong; Liang, Tao; Jiang, Xiaobing; Wang, Min Jie; Yao, Jin; Li, Jun Jun Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2025; Vol. 13, Issue 2, pp. -. DOI: 10.1136/jitc-2024-010782 PubMed DOI |
8. | Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens Author: Chen, Ming-Hui; Jiang, Jie; Chen, Hengyu; Wu, Ri-Hong; Xie, Weijing; Dai, Shu-Zhen; Zheng, Wu-Ping; Tan, Guang-Hong; Huang, Feng-Ying Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2025; Vol. 13, Issue 2, pp. -. DOI: 10.1136/jitc-2024-010150 PubMed DOI |
9. | Letter to the editor: effects of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer-a prospective observation study Author: Wang, Bi-Cheng Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2025; Vol. 13, Issue 2, pp. -. DOI: 10.1136/jitc-2025-011678 PubMed DOI |
10. | Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1/2 trial Author: Tan, Zhichao; Wu, Yan; Fan, Zhengfu; Gao, Tian; Ding, Sijuan; Han, Liang; Luo, Suxia; Fan, Qingxia; Shi, Jianhua; Bai, Chujie; Xue, Ruifeng; Li, Shu; Zhang, Lu; Wang, Xinyu; Jia, Ling; Zhou, Lixin; Liu, Binlei; Huang, Jing; Liu, Jiayong Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2025; Vol. 13, Issue 1, pp. -. DOI: 10.1136/jitc-2024-010543 PubMed DOI |
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2025 中国: LetPub上海 网站备案号:沪ICP备10217908号-1 沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)
增值电信业务经营许可证:沪B2-20211595 网络文化经营许可证:沪网文[2023]2004-152号
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室